Xenon Pharmaceuticals Inc. – NASDAQ:XENE
Xenon Pharmaceuticals stock price today
$37.36
-1.46
-3.79%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
Xenon Pharmaceuticals stock price monthly change
-9.53%
month
Xenon Pharmaceuticals stock price quarterly change
-9.53%
quarter
Xenon Pharmaceuticals stock price yearly change
-16.42%
year
Xenon Pharmaceuticals key metrics
Market Cap | 2.90B |
Enterprise value | N/A |
P/E | -17.01 |
EV/Sales | -4.73 |
EV/EBITDA | 0.52 |
Price/Sales | 0.22 |
Price/Book | N/A |
PEG ratio | 1.03 |
EPS | -2.71 |
Revenue | N/A |
EBITDA | -222.59M |
Income | -188.59M |
Revenue Q/Q | N/A |
Revenue Y/Y | 694.95% |
Profit margin | -932.94% |
Oper. margin | -909.22% |
Gross margin | 0% |
EBIT margin | -909.22% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeXenon Pharmaceuticals stock price history
Xenon Pharmaceuticals stock forecast
Xenon Pharmaceuticals financial statements
Average Price Target
$50.67
Potential upside: 35.61%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -47.46M | |
|---|---|---|---|
| Sep 2023 | 0 | -48.46M | |
| Dec 2023 | 5.38M | -44.74M | -831.65% |
| Mar 2024 | 0 | -47.93M |
| Jun 2023 | 684899000 | 38.44M | 5.61% |
|---|---|---|---|
| Sep 2023 | 671093000 | 34.50M | 5.14% |
| Dec 2023 | 964798000 | 36.87M | 3.82% |
| Mar 2024 | 919023000 | 31.32M | 3.41% |
| Jun 2023 | -33.22M | 27.90M | 0 |
|---|---|---|---|
| Sep 2023 | -42.23M | 48.03M | 29.50M |
| Dec 2023 | -33.68M | -239.18M | 320.69M |
| Mar 2024 | -43.17M | -46.20M | 0 |
Xenon Pharmaceuticals alternative data
| Aug 2023 | 203 |
|---|---|
| Sep 2023 | 203 |
| Oct 2023 | 203 |
| Nov 2023 | 203 |
| Dec 2023 | 203 |
| Jan 2024 | 203 |
| Feb 2024 | 203 |
| Mar 2024 | 251 |
| Apr 2024 | 251 |
| May 2024 | 251 |
| Jun 2024 | 251 |
| Jul 2024 | 251 |
Xenon Pharmaceuticals other data
100.00%
0.00%
of XENE is owned by hedge funds
131
+3
49.18M
+1.53M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 0 | 22229 |
| Nov 2024 | 0 | 4891 |
| Dec 2024 | 0 | 18709 |
| Patent |
|---|
Application Filling date: 9 Feb 2022 Issue date: 25 Aug 2022 |
Application Filling date: 22 Nov 2021 Issue date: 23 Jun 2022 |
Grant Filling date: 13 Jul 2020 Issue date: 10 May 2022 |
Grant Filling date: 28 Jul 2020 Issue date: 12 Apr 2022 |
Application Filling date: 1 Oct 2021 Issue date: 3 Mar 2022 |
Application Filling date: 6 Jul 2021 Issue date: 3 Mar 2022 |
Application Filling date: 6 Aug 2021 Issue date: 24 Feb 2022 |
Grant Filling date: 3 Sep 2020 Issue date: 21 Dec 2021 |
Grant Filling date: 2 Mar 2020 Issue date: 16 Nov 2021 |
Grant Filling date: 3 Dec 2019 Issue date: 19 Oct 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Simon N. Pimstone FRCPC, M.B. ChB., M.D., Ph.D. (1968) Executive Chairman | $787,780 |
Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA (1976) Pres, Chief Executive Officer & Director | $667,550 |
Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data
Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential
Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth
Xenon: MDD Data Provides Rationale For XEN1101 Advancement Towards FOS
Xenon Pharmaceuticals: XEN1101 Remains A Gem Despite The Dip
Xenon Pharmaceuticals: Upcoming Phase Two Major Depressive Disorder Data Readout Represents An Opportunity
Xenon Is Well-Funded Heading Into Key Readouts
Xenon Pharmaceuticals: Navigating The Neural Network Of Epilepsy And Depression
Xenon May Have A Surprise In Store For Major Depressive Disorder
-
What's the price of Xenon Pharmaceuticals stock today?
One share of Xenon Pharmaceuticals stock can currently be purchased for approximately $37.36.
-
When is Xenon Pharmaceuticals's next earnings date?
Unfortunately, Xenon Pharmaceuticals's (XENE) next earnings date is currently unknown.
-
Does Xenon Pharmaceuticals pay dividends?
No, Xenon Pharmaceuticals does not pay dividends.
-
How much money does Xenon Pharmaceuticals make?
Xenon Pharmaceuticals has a market capitalization of 2.90B.
-
What is Xenon Pharmaceuticals's stock symbol?
Xenon Pharmaceuticals Inc. is traded on the NASDAQ under the ticker symbol "XENE".
-
What is Xenon Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Xenon Pharmaceuticals?
Shares of Xenon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Xenon Pharmaceuticals's key executives?
Xenon Pharmaceuticals's management team includes the following people:
- Dr. Simon N. Pimstone FRCPC, M.B. ChB., M.D., Ph.D. Executive Chairman(age: 57, pay: $787,780)
- Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA Pres, Chief Executive Officer & Director(age: 49, pay: $667,550)
-
How many employees does Xenon Pharmaceuticals have?
As Jul 2024, Xenon Pharmaceuticals employs 251 workers.
-
When Xenon Pharmaceuticals went public?
Xenon Pharmaceuticals Inc. is publicly traded company for more then 10 years since IPO on 5 Nov 2014.
-
What is Xenon Pharmaceuticals's official website?
The official website for Xenon Pharmaceuticals is xenon-pharma.com.
-
Where are Xenon Pharmaceuticals's headquarters?
Xenon Pharmaceuticals is headquartered at 3650 Gilmore Way, Burnaby, BC.
-
How can i contact Xenon Pharmaceuticals?
Xenon Pharmaceuticals's mailing address is 3650 Gilmore Way, Burnaby, BC and company can be reached via phone at +1 604 484 3300.
-
What is Xenon Pharmaceuticals stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Xenon Pharmaceuticals in the last 12 months, the avarage price target is $50.67. The average price target represents a 35.61% change from the last price of $37.36.
Xenon Pharmaceuticals company profile:
Xenon Pharmaceuticals Inc.
xenon-pharma.comExchange:
NASDAQ
Full time employees:
251
Industry:
Biotechnology
Sector:
Healthcare
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
3650 Gilmore Way
Burnaby, BC V5G 4W8
Burnaby, BC V5G 4W8
CIK: 0001582313
ISIN: CA98420N1050
CUSIP: 98420N105
